Israel’s Bonus Biogroup (see here previously) is the first Israeli company ever to receive an Advanced Therapies Award, winning in the Cell Therapy Biotech Innovation category. Bonus Biotech has two products in advanced human trials – MesenCure and BonoFill. https://www.israel21c.org/first-ever-israeli-win-in-advanced-therapies-award-event/ … Continue reading →

MesenCure – the life-saving Covid-19 treatment from Israel’s Bonus BioGroup (see here) also prevents a lethal inflammatory response that affects cancer patients receiving immunotherapy. In California trials MesenCure significantly reduced an overreaction of the immune system. https://worldisraelnews.com/israeli-covid-drug-also-aids-cancer-immunotherapy-patients/

In its latest Phase 2 trial at three major Israeli hospitals, MesenCure from Israel’s Bonus BioGroup (see here previously) reduced Covid-19 deaths to 6.7% compared to 23.3% of the control group. It is now aiming for emergency use authorization in … Continue reading →

Israel’s Health Ministry has approved a Phase 2 trial of Covid-19 treatment MesenCure (see here previously) from Israel’s Bonus BioGroup. The treatment helped 15 out of 17 severe Covid cases, to be released from hospital just one day after receiving … Continue reading →

Israel’s Bonus BioGroup (see here previously) tested its MesenCure MSC treatment on 10 severely ill, high risk Covid-19 patients at Haifa’s Rambam hospital. All ten improved sufficiently to be discharged just one day after treatment. MesenCure now advances to Phase … Continue reading →

While developing its unique treatment for growing human bone grafts, Israel’s Bonus BioGroup (see previously) discovered MesenCure – a new pneumonia treatment that could help coronavirus patients. A study on animals was successful; human trials are planned. https://unitedwithisrael.org/israeli-bone-grafting-company-makes-breakthrough-in-treatment-for-coronavirus/